An early-stage company with expertise in next generation nucleic acid extraction would like BCBA to explore NGS and diagnostics markets for complex sample analysis including FFPE and cell free DNA. To that end, the BCBA project team will 1) identify target customer profiles and 2) generate VOC for these profiles to understand each application’s value […]

An early-stage contract research organization (CRO) is providing high-throughput molecular structure determination services using a cutting-edge platform, enabling them to determine structures cheaper and more quickly than many competitors. The company believes that these advantages will enable them to capture a significant proportion of the molecular structure determination market, and that a large market opportunity […]

An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]

A direct-to-consumer (DTC) diagnostics company is developing a blood test panel for the assessment of chronic inflammation. Using a cutting-edge AI-based platform, the company is optimizing a panel that can provide their customers with deep insights on their inflammatory status with only a few drops of blood. Given the massive increase in DTC and telemedicine […]

The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]

The BCBA project team will conduct a survey to evaluate and prioritize cardiovascular, metabolic, and neuro indications for an early stage company’s target discovery platform that leverages the power of comparative biology to develop therapeutics.

An early-stage biotechnology company with expertise in antibody therapeutics development is engaging BCBA to explore the GPCR-targeted therapeutics market. To that end, the BCBA project team will 1) conduct a comprehensive market landscape analysis of the GPCR therapeutic market to understand the market conditions and requirements for the development of compelling Proof-of-Concept (POC) programs in […]

The project team will analyze the market opportunity for a novel NGS library preparation kit for Illumina NGS systems that, in addition to primary sequence, captures long-range information enabling large structural variant detection and haplotype phasing along with 3D chromatin architecture.